ZA200501974B - T-cell epitopes in erythropoietin - Google Patents
T-cell epitopes in erythropoietin Download PDFInfo
- Publication number
- ZA200501974B ZA200501974B ZA200501974A ZA200501974A ZA200501974B ZA 200501974 B ZA200501974 B ZA 200501974B ZA 200501974 A ZA200501974 A ZA 200501974A ZA 200501974 A ZA200501974 A ZA 200501974A ZA 200501974 B ZA200501974 B ZA 200501974B
- Authority
- ZA
- South Africa
- Prior art keywords
- epo
- molecule
- peptide
- cell
- modified
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 95
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title claims description 92
- 108090000394 Erythropoietin Proteins 0.000 title claims description 72
- 102000003951 Erythropoietin Human genes 0.000 title claims description 69
- 229940105423 erythropoietin Drugs 0.000 title claims description 62
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 181
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 78
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 claims abstract description 23
- 102000044890 human EPO Human genes 0.000 claims abstract description 21
- 230000005847 immunogenicity Effects 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims description 58
- 108090000623 proteins and genes Proteins 0.000 claims description 57
- 108091054438 MHC class II family Proteins 0.000 claims description 56
- 102000004169 proteins and genes Human genes 0.000 claims description 53
- 102000043131 MHC class II family Human genes 0.000 claims description 51
- 239000003446 ligand Substances 0.000 claims description 49
- 238000006467 substitution reaction Methods 0.000 claims description 44
- 238000003556 assay Methods 0.000 claims description 38
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 31
- 230000000638 stimulation Effects 0.000 claims description 27
- 210000004027 cell Anatomy 0.000 claims description 24
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 22
- 230000006044 T cell activation Effects 0.000 claims description 17
- 230000002163 immunogen Effects 0.000 claims description 17
- 210000004296 naive t lymphocyte Anatomy 0.000 claims description 17
- 238000012360 testing method Methods 0.000 claims description 14
- 125000000539 amino acid group Chemical group 0.000 claims description 13
- 230000004071 biological effect Effects 0.000 claims description 12
- 238000000338 in vitro Methods 0.000 claims description 12
- 102000036639 antigens Human genes 0.000 claims description 11
- 108091007433 antigens Proteins 0.000 claims description 11
- 230000006052 T cell proliferation Effects 0.000 claims description 10
- 238000001516 cell proliferation assay Methods 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 239000000427 antigen Substances 0.000 claims description 8
- 238000001727 in vivo Methods 0.000 claims description 8
- 230000004048 modification Effects 0.000 claims description 8
- 238000012986 modification Methods 0.000 claims description 8
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 7
- 238000004458 analytical method Methods 0.000 claims description 6
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 108020004414 DNA Proteins 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 108091005601 modified peptides Proteins 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 102000053602 DNA Human genes 0.000 claims 2
- 101100001672 Emericella variicolor andG gene Proteins 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 108010092408 Eosinophil Peroxidase Proteins 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 51
- 101100347633 Drosophila melanogaster Mhc gene Proteins 0.000 description 34
- 235000001014 amino acid Nutrition 0.000 description 29
- 150000001413 amino acids Chemical class 0.000 description 18
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 description 14
- 102100038823 RNA-binding protein 45 Human genes 0.000 description 14
- 238000013459 approach Methods 0.000 description 12
- 238000000126 in silico method Methods 0.000 description 11
- 229920001184 polypeptide Polymers 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 108091008874 T cell receptors Proteins 0.000 description 8
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 230000028993 immune response Effects 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 101150034979 DRB3 gene Proteins 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 101100278514 Oryza sativa subsp. japonica DRB2 gene Proteins 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 5
- 108020004511 Recombinant DNA Proteins 0.000 description 5
- 230000004075 alteration Effects 0.000 description 5
- 208000007502 anemia Diseases 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 230000001010 compromised effect Effects 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 230000008030 elimination Effects 0.000 description 5
- 238000003379 elimination reaction Methods 0.000 description 5
- 238000013507 mapping Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 102000015636 Oligopeptides Human genes 0.000 description 4
- 108010038807 Oligopeptides Proteins 0.000 description 4
- 238000004166 bioassay Methods 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 102000035118 modified proteins Human genes 0.000 description 4
- 108091005573 modified proteins Proteins 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000009696 proliferative response Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 239000012997 ficoll-paque Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 238000013102 re-test Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 229940104230 thymidine Drugs 0.000 description 3
- 241000606161 Chlamydia Species 0.000 description 2
- 101000738180 Euglena gracilis Chaperonin CPN60, mitochondrial Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 208000003670 Pure Red-Cell Aplasia Diseases 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000002153 concerted effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000763 evoking effect Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 102220264453 rs201314211 Human genes 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- 238000003211 trypan blue cell staining Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 102100022276 60S ribosomal protein L35a Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010002913 Asialoglycoproteins Proteins 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 102210012675 DRB1*15 Human genes 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 101150002621 EPO gene Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 101001110988 Homo sapiens 60S ribosomal protein L35a Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 108010078049 Interferon alpha-2 Proteins 0.000 description 1
- 102100039350 Interferon alpha-7 Human genes 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- 101100117565 Oryza sativa subsp. japonica DRB4 gene Proteins 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 102220470514 Proteasome subunit beta type-3_V82A_mutation Human genes 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 101710145796 Staphylokinase Proteins 0.000 description 1
- 108090000787 Subtilisin Proteins 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 102200156642 c.77G>C Human genes 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000003013 erythroid precursor cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 102000014187 peptide receptors Human genes 0.000 description 1
- 108010011903 peptide receptors Proteins 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 102200153349 rs104894823 Human genes 0.000 description 1
- 102220194848 rs1057517575 Human genes 0.000 description 1
- 102220290891 rs1313810606 Human genes 0.000 description 1
- 102220013590 rs17853498 Human genes 0.000 description 1
- 102220138882 rs188916371 Human genes 0.000 description 1
- 102200082877 rs33935445 Human genes 0.000 description 1
- 102220032811 rs367543159 Human genes 0.000 description 1
- 102220097795 rs535274413 Human genes 0.000 description 1
- 102220064657 rs786205565 Human genes 0.000 description 1
- 102220072205 rs794728064 Human genes 0.000 description 1
- 102220088393 rs869025622 Human genes 0.000 description 1
- 102220095237 rs876659353 Human genes 0.000 description 1
- 102220103278 rs878854729 Human genes 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000024664 tolerance induction Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02017914 | 2002-08-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200501974B true ZA200501974B (en) | 2006-03-29 |
Family
ID=31896824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200501974A ZA200501974B (en) | 2002-08-09 | 2006-01-10 | T-cell epitopes in erythropoietin |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20060035322A1 (fr) |
| EP (1) | EP1527094B1 (fr) |
| JP (1) | JP2006515161A (fr) |
| KR (1) | KR20060003853A (fr) |
| CN (1) | CN1675242A (fr) |
| AT (1) | ATE401344T1 (fr) |
| AU (1) | AU2003263201A1 (fr) |
| BR (1) | BR0313135A (fr) |
| CA (1) | CA2494963A1 (fr) |
| DE (1) | DE60322225D1 (fr) |
| ES (1) | ES2310684T3 (fr) |
| MX (1) | MXPA05001452A (fr) |
| PL (1) | PL372862A1 (fr) |
| RU (1) | RU2005106841A (fr) |
| WO (1) | WO2004018515A2 (fr) |
| ZA (1) | ZA200501974B (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60332358D1 (de) * | 2002-09-09 | 2010-06-10 | Hanall Pharmaceutical Co Ltd | Protease-resistente modifizierte interferon alpha polypeptide |
| WO2006029094A2 (fr) * | 2004-09-02 | 2006-03-16 | Xencor, Inc. | Derives d'erythropoietine a antigenicite modifiee |
| US8653028B2 (en) * | 2005-04-29 | 2014-02-18 | Rui Rong Yuan | Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators |
| US9345745B2 (en) | 2005-04-29 | 2016-05-24 | Bo Wang | Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides |
| EP2377884A1 (fr) * | 2005-05-10 | 2011-10-19 | Neoloch Aps | Peptides neuritogènes |
| JP2010510794A (ja) | 2006-11-28 | 2010-04-08 | ハナル ファーマシューティカル カンパニー リミテッド | 修飾型エリスロポエチンポリペプチド及びこの治療用用途 |
| US20090010966A1 (en) * | 2007-06-21 | 2009-01-08 | Angelica Therapeutics, Inc. | Modified diphtheria toxins |
| EP2268297A4 (fr) * | 2008-02-29 | 2011-11-16 | Angelica Therapeutics Inc | Toxines modifiées |
| US10059750B2 (en) | 2013-03-15 | 2018-08-28 | Angelica Therapeutics, Inc. | Modified toxins |
| JP6479789B2 (ja) * | 2013-07-17 | 2019-03-13 | アライム ファーマシューティカルズ，インコーポレーテッド | 組織の損傷に関連した疾患及び障害を予防及び治療する、組織保護ペプチド及びペプチド類似体 |
| CN106554395B (zh) * | 2015-09-30 | 2019-08-16 | 天津药物研究院有限公司 | 一种长效促红细胞生成素模拟肽及其制备方法和应用 |
| AR113091A1 (es) * | 2018-09-27 | 2020-01-22 | Univ Nacional Del Litoral | Eritropoyetina humana modificada |
| EP4208186A1 (fr) * | 2020-09-04 | 2023-07-12 | Dompe' Farmaceutici SpA | Peptides pourvus d'une activité angiogénique |
| EP3964225A1 (fr) * | 2020-09-04 | 2022-03-09 | Dompe' Farmaceutici S.P.A. | Peptides dotés d'une activité angiogénique |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4954437A (en) * | 1986-09-15 | 1990-09-04 | Integrated Genetics, Inc. | Cell encoding recombinant human erythropoietin |
| US4835260A (en) * | 1987-03-20 | 1989-05-30 | Genetics Institute, Inc. | Erythropoietin composition |
| DE3924746A1 (de) * | 1989-07-26 | 1991-01-31 | Behringwerke Ag | Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper |
| NZ244778A (en) * | 1991-10-21 | 1994-03-25 | Ortho Pharma Corp | Peg imidates and protein derivatives thereof |
| EP1051432B1 (fr) * | 1998-12-08 | 2007-01-24 | Biovation Limited | Modification de l'immunogenicite de proteines |
| CA2288341C (fr) * | 1998-12-17 | 2005-01-04 | Pfizer Products Inc. | Erythropoietine dans le traitement de l'anemie chez les animaux domestiques et le betail |
| CN1454097A (zh) * | 2000-09-08 | 2003-11-05 | 格莱风治疗公司 | 聚合物修饰的合成的蛋白质类 |
| PL362396A1 (en) * | 2001-02-06 | 2004-11-02 | Merck Patent Gmbh | Modified erythropoietin (epo) with reduced immunogenicity |
| HUP0303199A2 (hu) * | 2001-02-19 | 2003-12-29 | Merck Patent Gmbh | Eljárás T-sejt-epitópok azonosítására és csökkentett immunogenitású molekulák előállítására |
-
2003
- 2003-08-07 EP EP03792268A patent/EP1527094B1/fr not_active Expired - Lifetime
- 2003-08-07 ES ES03792268T patent/ES2310684T3/es not_active Expired - Lifetime
- 2003-08-07 KR KR1020057002338A patent/KR20060003853A/ko not_active Application Discontinuation
- 2003-08-07 DE DE60322225T patent/DE60322225D1/de not_active Expired - Lifetime
- 2003-08-07 CN CNA038189690A patent/CN1675242A/zh active Pending
- 2003-08-07 WO PCT/EP2003/008725 patent/WO2004018515A2/fr active IP Right Grant
- 2003-08-07 BR BR0313135-1A patent/BR0313135A/pt not_active IP Right Cessation
- 2003-08-07 JP JP2004530097A patent/JP2006515161A/ja not_active Withdrawn
- 2003-08-07 RU RU2005106841/13A patent/RU2005106841A/ru not_active Application Discontinuation
- 2003-08-07 MX MXPA05001452A patent/MXPA05001452A/es not_active Application Discontinuation
- 2003-08-07 US US10/522,297 patent/US20060035322A1/en not_active Abandoned
- 2003-08-07 CA CA002494963A patent/CA2494963A1/fr not_active Abandoned
- 2003-08-07 AT AT03792268T patent/ATE401344T1/de not_active IP Right Cessation
- 2003-08-07 AU AU2003263201A patent/AU2003263201A1/en not_active Abandoned
- 2003-08-07 PL PL03372862A patent/PL372862A1/xx not_active Application Discontinuation
-
2006
- 2006-01-10 ZA ZA200501974A patent/ZA200501974B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2310684T3 (es) | 2009-01-16 |
| WO2004018515A3 (fr) | 2004-06-03 |
| EP1527094B1 (fr) | 2008-07-16 |
| KR20060003853A (ko) | 2006-01-11 |
| RU2005106841A (ru) | 2005-10-27 |
| WO2004018515A2 (fr) | 2004-03-04 |
| CA2494963A1 (fr) | 2004-03-04 |
| BR0313135A (pt) | 2005-07-05 |
| AU2003263201A1 (en) | 2004-03-11 |
| CN1675242A (zh) | 2005-09-28 |
| PL372862A1 (en) | 2005-08-08 |
| US20060035322A1 (en) | 2006-02-16 |
| DE60322225D1 (en) | 2008-08-28 |
| ATE401344T1 (de) | 2008-08-15 |
| MXPA05001452A (es) | 2005-06-06 |
| JP2006515161A (ja) | 2006-05-25 |
| EP1527094A2 (fr) | 2005-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200501974B (en) | T-cell epitopes in erythropoietin | |
| ZA200502273B (en) | T-cell epitopes in staphylococcal enterotoxin B. | |
| CA2457429A1 (fr) | Facteur ix modifie | |
| KR20040103970A (ko) | 변형된 펙터 ⅷ | |
| KR20230019859A (ko) | 펩타이드 칵테일 | |
| US20050181459A1 (en) | Method for mapping and eliminating T cell epitopes | |
| MX2007005808A (es) | Formulaciones inmunoterapeuticas para la induccion de autoanticuerpos bloqueadores de la union de interleucina-2 a su receptor, su uso en el tratamiento del cancer. | |
| CA2459138A1 (fr) | Hormone de croissance humaine modifiee | |
| US20050074863A1 (en) | T-cell epitodes in carboxypeptidase g2 | |
| KR20050010898A (ko) | 감소된 면역원성을 갖는 개질 브리오딘 1 | |
| EP1512004B1 (fr) | Methode de cartographie et d'elimination des epitopes t | |
| CN109306004B (zh) | 骨保护素的s77突变体蛋白及其相关产品与应用 | |
| CN109306002B (zh) | 骨保护素的n139突变体蛋白及其相关产品与应用 | |
| AU2002331095A1 (en) | Modified factor IX | |
| AU2002336095A1 (en) | Modified human growth hormone |